Theory Paper IIIDrNB Cardiology – Theory Notes
BARE METAL STENTS (BMS): ROLE AND CLINICAL SCENARIOS
ICORE CONCEPTS AND THE “DES REVOLUTION”
- The Clinical Decline: Since the introduction of second- and third-generation Drug-Eluting Stents (DES), the clinical use of Bare Metal Stents (BMS) has declined to a very small fraction of all PCIs.
- Pathophysiology of BMS Failure: Because BMS lack an antiproliferative drug coating (such as Sirolimus, Everolimus, or Zotarolimus), they are associated with high rates of In-Stent Restenosis (ISR) driven by uncontrolled vascular smooth muscle cell proliferation and neointimal hyperplasia.
IIHISTORICAL CLINICAL SCENARIOS FOR BMS
- Short Dual Antiplatelet Therapy (DAPT) Requirement: Historically, BMS were selected when only 1 month of DAPT could be tolerated, whereas early first-generation DES required 6 to 12 months of DAPT:
- High Bleeding Risk (HBR): Patients with active bleeding risks or those requiring long-term oral anticoagulation.
- Urgent Non-Cardiac Surgery: Patients requiring major non-cardiac surgery within 4 to 6 weeks of PCI to minimize stent thrombosis during DAPT interruption.
- Medication Non-Adherence: Patients deemed unable to comply with a prolonged 6-to-12-month DAPT regimen.
IIITHE PARADIGM SHIFT: THE OBSOLESCENCE OF BMS
- Neutralization of the “Short-DAPT” BMS Advantage: Landmark randomized trials using contemporary thin-strut polymer-free or biocompatible-polymer DES proved that 1 month of DAPT is safe with modern DES, completely eliminating the historical rationale for BMS:
- LEADERS FREE Trial: Proved that in High Bleeding Risk (HBR) patients treated with a strict 1-month DAPT regimen, a polymer-free Drug-Coated Stent (BioFreedom) was both safer and more effective (significantly lower clinically driven target lesion revascularization and MI) than a BMS.
- ONYX ONE Trial: Demonstrated that a durable-polymer Zotarolimus-Eluting Stent (Resolute Onyx) was non-inferior to the BioFreedom stent with only 1 month of DAPT in HBR patients.
- SENIOR Trial: Confirmed that in elderly patients aged 75 years or older, implanting a bioabsorbable-polymer DES with a short DAPT regimen (1 month in stable CAD, 6 months in ACS) significantly reduced Major Adverse Cardiovascular Events (MACE) and repeat revascularization compared to BMS.
- MASTER DAPT Trial: Validated that abbreviated 1-month DAPT following biodegradable-polymer Sirolimus-Eluting Stent implantation in HBR patients was non-inferior for net and ischemic clinical events while significantly reducing major or clinically relevant non-major bleeding.
| Landmark Trial | Target Population | Stent & DAPT Regimen | Definitive Clinical Finding |
|---|---|---|---|
| LEADERS FREE | High Bleeding Risk (HBR) patients | BioFreedom (DCS) vs. BMS with 1-month DAPT | BioFreedom superior to BMS for both efficacy (lower TLR) and safety (lower MI/stent thrombosis) |
| ONYX ONE | High Bleeding Risk (HBR) patients | Resolute Onyx (DES) with 1-month DAPT | Proved safety and efficacy of polymer-based DES with 1-month DAPT in HBR cohorts |
| SENIOR | Elderly patients (>= 75 years old) | DES vs. BMS with 1- to 6-month DAPT | DES significantly reduced MACE and repeat revascularization without increasing bleeding |
| MASTER DAPT | High Bleeding Risk (HBR) patients | Modern DES with 1-month vs. standard DAPT | 1-month DAPT preserved ischemic protection while significantly reducing bleeding |
IVCONTEMPORARY GUIDELINES AND RARE RESIDUAL SCENARIOS
- Stent-Type-Independent DAPT Guidelines: Contemporary ESC and ACC/AHA guidelines recommend new-generation DES over BMS across all patient and lesion subsets (Class I), with DAPT duration dictated entirely by the patient’s ischemic versus bleeding risk profile (ARC-HBR criteria) rather than stent type.
- Rare Residual Circumstances:
- Severe Resource Constraints: Extremely resource-limited settings where DES are unavailable.
- Documented Hypersensitivity: Extremely rare patients with documented severe allergy to specific antiproliferative drugs or polymers used on DES. (Note: Even in large-diameter vessels exceeding 4.0 mm, modern DES remain superior to BMS for preventing restenosis.)
VTHE INDIAN CLINICAL CONTEXT
- Universal DES Coverage in Public Schemes: National and state public health insurance programs in India (such as Ayushman Bharat) and NPPA price caps cover modern Drug-Eluting Stents, rendering BMS virtually obsolete in both public and private Indian catheterization laboratories.
- Managing the High-Bleeding-Risk Indian Patient: In elderly Indian patients or those at high risk for gastrointestinal bleeding, the evidence-based strategy is implantation of a modern DES followed by abbreviated 1-to-3-month DAPT (per the MASTER DAPT protocol) rather than implanting a BMS.
Key references
- Urban P, Meredith IT, Abizaid A, et al. (LEADERS FREE Investigators): Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk, New England Journal of Medicine.
- Varenne O, Cook S, Sideris G, et al. (SENIOR Investigators): Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial, The Lancet.
- Valgimigli M, Frigoli E, Heg D, et al. (MASTER DAPT Investigators): Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk, New England Journal of Medicine.
meritmedscript.comDr. Sidhartha Mullapudi
